Study of Long-term HFNC for COPD Patients With HOT

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial

— FLOCOP  

Official title:

Efficacy and Safety of Long-term High-flow Nasal Cannula Oxygen Therapy in Stable COPD Patients With Home Oxygen Therapy (HOT): a Multicenter, Prospective, Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03282019
• Other study ID #: TRIRES1668
• Secondary ID: UMIN000028581
• Status: Completed
• Phase: N/A
• Start date: September 6, 2017
• Est. completion date: October 28, 2020

Study information

• Verified date: January 2021
• Source: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized parallel study for evaluation of the efficacy and safety of long-term nocturnal high-flow nasal cannula therapy (HFNC: with the myAIRVO2 as HFNC in this study) in stable COPD patients with the global initiative for chronic obstructive lung disease (GOLD) stage 2-4, PaCO2 >= 45 Torr and hypercapnia who require home oxygen therapy (HOT) using COPD exacerbation (Moderate or Severe).

Description:

An abroad study of the stable COPD patients was reported that HFNC usage decreased the frequency of COPD exacerbation. In addition, the result of the pilot study (NCT02545855) of the stable COPD patient in Japan is indicated that HOT with HFNC improved their QOL and PaCO2 by comparing to HOT only. Therefore, this study is planned to indicate the efficacy of HFNC which can increase the ventilation efficiency and have the function of heated humidification, by comparing HOT with HFNC to HOT only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: October 28, 2020
• Est. primary completion date: October 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Patients who are diagnosed with the global initiative on obstructive lung disease (GOLD) stage 2-4 COPD.

2. Patients who have received nocturnal HOT 16 hours or more per day for 1 month or more at the time of the informed consent.

3. Patients with PaCO2 >= 45 Torr and pH >= 7.35 at screening.

4. Patients with COPD exacerbation (Moderate or Severe; judged by the investigators) within the past 1 year prior to the informed consent.

5. Patients who are more than 40 years old at the time of the informed consent.

6. Patients who agree to participate in the study with the written informed consent.

Exclusion Criteria:

1. Patients with severe kidney, liver or cardiovascular disease.

2. Patients with active malignant tumor.

3. Patients with acute disease.

4. Patients who are diagnosed with asthma. (Excluding COPD patients with history of asthma).

5. Patients who have any history of obstructive sleep apnea syndrome (OSAS) or are highly-suspected cases in the clinical. (Excluding patients who are denied the diagnosis of OSAS by the result of overnight polysomnography.)

6. Patients with diseases that affecting the efficacy endpoints (for example: active pulmonary infection, clinically significant pulmonary fibrosis and bronchiectasis, a-1-antitrypsin deficiency etc.,) and are regarded as inadequate for the study by the investigators.

7. Patients who have experienced a COPD exacerbation (any Severity: judged by the investigators) within the past 4 weeks prior to the informed consent.

8. Patients who are receiving nocturnal noninvasive positive pressure ventilation (NPPV), or who had been received it within 4 weeks prior to the informed consent.

9. Patients who have used HFNC at home within the past 1 year prior to the informed consent, or are using any HFNC. (Excluding patients who used HFNC during hospitalization due to acute respiratory failure within 1 year prior to the informed consent.)

10. Patients with history of tracheotomy, severe pharyngeal surgery or severe nasal cavity surgery within the past 6 months prior to the informed consent.

11. Patients who are pregnant.

12. Patients with cognitive impairment or mental disorder who are regarded as inadequate to evaluate for the study by the investigators.

13. Patients who are regarded as being unable to operate the myAIRVO2 adequately at home by the investigators.

14. Patients who have participated in the other study at the time of the informed consent, or will participate in the other study.

15. Any other cases who are regarded as inadequate for the study enrollment by the investigators.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Device:
• High-flow nasal cannula therapy
Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
• Home oxygen therapy (HOT)
All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.

Locations

Country	Name	City	State
Japan	Kobe City Medical Center General Hospital	Kobe	Hyogo

Sponsors (2)

Lead Sponsor	Collaborator
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Kobe City Medical Center General Hospital

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlation between frequency of COPD exacerbation (All Severity and Severe only) and amount of ABG change	Amount of ABG change will be calculated by the ABG value at before and after the intervention.	52weeks
Other	Correlation between frequency of COPD exacerbation (All Severity and Severe only) and amount of SpO2 change	Amount of SpO2 change will be calculated by the ABG value of before and after the intervention.	52weeks
Primary	Frequency (the number of occurrences per year) of COPD exacerbation (Moderate or Severe)	COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.	52weeks
Secondary	Term from enrollment to the date of first COPD exacerbation (Moderate or Severe)	The term from enrollment to the date of first COPD exacerbation is a duration from the start of intervention (Week0) to the date of first COPD exacerbation or death from any cause which ever comes first.; The date of first COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.	up to 52 weeks
Secondary	Term from enrollment to death from any cause	Term from enrollment to death from any cause is a duration from the start of intervention (Week0) to death from any cause.	up to 52 weeks
Secondary	Frequency (the number of occurrences per year) of COPD exacerbation (All Severity and Severe only)	COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.	52weeks
Secondary	Total St. George's respiratory questionnaire (SGRQ-C) score, and each components score (symptom score, activity score, and impact score)	SGRQ-C score will be assessed by Japanese version of the SGRQ-C value sets including each components score (symptom score, activity score, and impact score).	at 0, 12, 24 and 52 weeks
Secondary	Quality-adjusted life year (QALY) by mapping the EQ-5D-5L utility scores	Quality-adjusted life year (QALY) of the subjects will be assessed by Japanese version of the EQ-5D-5L value sets including assessment of changes from baseline in the EQ-5D-5L utility index scores and visual analogue scale scores.	at 0, 12, 24 and 52 weeks
Secondary	Total SRI (Severe Respiratory Insufficiency Questionnaire) score	Total SRI score will be assessed by Japanese version of the SRI value sets.	at 0, 12, 24 and 52 weeks
Secondary	Total PSQI-J(Japanese version of the Pittsburgh Sleep Quality Index) score	Total PSQI-J score will be assessed by Japanese version of the PSQI value sets.	at 0, 12, 24 and 52 weeks
Secondary	Dyspnea intensity: the modified medical research council (mMRC) score	Dyspnea intensity will be evaluated by the modified medical research council (mMRC) score.	52weeks
Secondary	Arterial blood gas analysis (ABG): pH, PaO2, PaCO2, HCO3-, BE	ABG will be evaluated by the blood gas analysis equipment.	52weeks
Secondary	Oxygen Saturation (SpO2)	SpO2 will be evaluated by Pulse Oximeter.	52weeks
Secondary	Pulmonary functions: FVC, FEV1, FEV1%	Lung function of the subjects will be assessed by the pulmonary function tests in the following indicators: vital capacity (VC, %VC), forced vital capacity (FVC, %FVC), forced expiratory volume in 1 second (FEV1, %FEV1), FEV1/FVC.	52weeks
Secondary	6-minute walk test (6MWT)	6MWT for the respiration rehabilitation is defined as the functional exercise capacity which is assessed by the following indicators: the distance (m), changes in pre- and post-6MWT pulse oximeter (SpO2), and post-6MWT modified borg scale.	at 0, 12, 24 and 52 weeks
Secondary	Term from enrollment to the date of long-term (more than 1month) NPPV(Noninvasive Positive Pressure Ventilation) usage	The term from the start of intervention (Week0) to the date of Long-term NPPV usage.; Long-term NPPV usage is defined as more than 1month NPPV usage.	52weeks
Secondary	Flow rate(Oxygen / Total) (Arm A only)	Oxygen flow rate / Total flow rate will be confirmed by the record of numerical value displayed on the device.	52weeks
Secondary	Total hours of myAIRVO2-use (Arm A only)	Total hours of myAIRVO2-use will be confirmed by the record of numerical value displayed on the device.	52weeks
Secondary	Adverse events	Adverse events will be determined by the latest version of MedDRA/J (Medical Dictionary for Regulatory Activities/J)at the time of Database lock.	52weeks